SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

Naser Eddin Gharaibeh, Marie-Noel Rahhal, Leili Rahimi, Faramarz Ismail-BeigiDepartment of Medicine, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USAAbstract: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a major expan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Fatty liver insulin resistance beta-oxidation liver biopsy de novo lipid synthesis Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/22d788df11744ba6b7f59009abbb9ec9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22d788df11744ba6b7f59009abbb9ec9
record_format	dspace
spelling	oai:doaj.org-article:22d788df11744ba6b7f59009abbb9ec92021-12-02T04:47:59ZSGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions1178-7007https://doaj.org/article/22d788df11744ba6b7f59009abbb9ec92019-07-01T00:00:00Zhttps://www.dovepress.com/sglt-2-inhibitors-as-promising-therapeutics-for-non-alcoholic-fatty-li-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Naser Eddin Gharaibeh, Marie-Noel Rahhal, Leili Rahimi, Faramarz Ismail-BeigiDepartment of Medicine, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USAAbstract: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a major expanding national and international health problem. Despite numerous investigations using a variety of therapeutic agents, the positive result on any single medication has not been established enough to gain widespread approval. This is in part related to concerns regarding side effects of agents, but is also related to the complex etiology of NAFLD. An often discussed question has been whether insulin resistance that is frequently present in those with NAFLD is a cause of NAFLD or is merely associated with the condition. Nevertheless, it is clear that a very high proportion of patients with NAFLD are obese, have elements of metabolic syndrome, or have type 2 diabetes (T2DM). Also, much progress has been made toward a better understanding of the pathophysiology of NAFLD. Life-style interventions resulting in weight loss remain the foundation for the prevention and treatment of NAFLD. In addition, agents such as Vitamin E and pioglitazone as well as other glycemia-lowering agents including Glucagon Like Peptide-1 (GLP-1) receptor agonists and Sodium Glucose Contransporter-2 inhibitors (SGLT-2i(s)) exhibit positive effects on the clinical course of NAFLD. This narrative review summarizes the current understanding of the diagnosis, epidemiology, and pathophysiology of NAFLD and specifically focuses on the efficacy of SGLT2i(s) as a potentially promising group of agents for the management of patients with NAFLD.Keywords: fatty liver, insulin resistance, beta-oxidation, liver biopsy, de novo lipid synthesis  Gharaibeh NERahhal MNRahimi LIsmail-Beigi FDove Medical PressarticleFatty liverinsulin resistancebeta-oxidationliver biopsyde novo lipid synthesisSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 1001-1012 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Fatty liver insulin resistance beta-oxidation liver biopsy de novo lipid synthesis Specialties of internal medicine RC581-951
spellingShingle	Fatty liver insulin resistance beta-oxidation liver biopsy de novo lipid synthesis Specialties of internal medicine RC581-951 Gharaibeh NE Rahhal MN Rahimi L Ismail-Beigi F SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
description	Naser Eddin Gharaibeh, Marie-Noel Rahhal, Leili Rahimi, Faramarz Ismail-BeigiDepartment of Medicine, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USAAbstract: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a major expanding national and international health problem. Despite numerous investigations using a variety of therapeutic agents, the positive result on any single medication has not been established enough to gain widespread approval. This is in part related to concerns regarding side effects of agents, but is also related to the complex etiology of NAFLD. An often discussed question has been whether insulin resistance that is frequently present in those with NAFLD is a cause of NAFLD or is merely associated with the condition. Nevertheless, it is clear that a very high proportion of patients with NAFLD are obese, have elements of metabolic syndrome, or have type 2 diabetes (T2DM). Also, much progress has been made toward a better understanding of the pathophysiology of NAFLD. Life-style interventions resulting in weight loss remain the foundation for the prevention and treatment of NAFLD. In addition, agents such as Vitamin E and pioglitazone as well as other glycemia-lowering agents including Glucagon Like Peptide-1 (GLP-1) receptor agonists and Sodium Glucose Contransporter-2 inhibitors (SGLT-2i(s)) exhibit positive effects on the clinical course of NAFLD. This narrative review summarizes the current understanding of the diagnosis, epidemiology, and pathophysiology of NAFLD and specifically focuses on the efficacy of SGLT2i(s) as a potentially promising group of agents for the management of patients with NAFLD.Keywords: fatty liver, insulin resistance, beta-oxidation, liver biopsy, de novo lipid synthesis
format	article
author	Gharaibeh NE Rahhal MN Rahimi L Ismail-Beigi F
author_facet	Gharaibeh NE Rahhal MN Rahimi L Ismail-Beigi F
author_sort	Gharaibeh NE
title	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
title_short	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
title_full	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
title_fullStr	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
title_full_unstemmed	SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
title_sort	sglt-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/22d788df11744ba6b7f59009abbb9ec9
work_keys_str_mv	AT gharaibehne sglt2inhibitorsaspromisingtherapeuticsfornonalcoholicfattyliverdiseasepathophysiologyclinicaloutcomesandfuturedirections AT rahhalmn sglt2inhibitorsaspromisingtherapeuticsfornonalcoholicfattyliverdiseasepathophysiologyclinicaloutcomesandfuturedirections AT rahimil sglt2inhibitorsaspromisingtherapeuticsfornonalcoholicfattyliverdiseasepathophysiologyclinicaloutcomesandfuturedirections AT ismailbeigif sglt2inhibitorsaspromisingtherapeuticsfornonalcoholicfattyliverdiseasepathophysiologyclinicaloutcomesandfuturedirections
_version_	1718400996169744384

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

Ejemplares similares